Tyropanoate: A diagnostic aid as a radiopaque medium in cholecystography. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 5611 |
CHEMBL ID | 1201261 |
CHEBI ID | 135862 |
SCHEMBL ID | 2788021 |
MeSH ID | M0022199 |
Synonym |
---|
27293-82-9 |
tyropanoic acid |
benzenepropanoic acid, .alpha.-ethyl-2,4, {6-triiodo-3-[(1-oxobutyl)amino]-,} monosodium salt |
tyropanoate sodium(usan |
hydrocinnamic acid, 3-butyramido-.alpha.-ethyl-2,4, 6-triiodo-, monosodium salt |
hydrocinnamic acid, 3-butyramido-.alpha.-ethyl-2,4,6-triiodo- |
hydrocinnamic acid, 3-butyramido-.alpha.-ethyl-2,4,6-triiodo-, sodium salt |
2-(3-(butyrylamino)-2,4,6-triiodobenzyl)butanoic acid |
2-[[3-(butanoylamino)-2,4,6-triiodo-phenyl]methyl]butanoic acid |
sodium 3-butyramido-.alpha.-ethyl-2,4,6-triiodohydrocinnamate |
sodium tyropanoate (usan) |
tyropanoate |
CHEBI:135862 |
2-[[3-(butanoylamino)-2,4,6-triiodophenyl]methyl]butanoic acid |
CHEMBL1201261 |
einecs 248-389-8 |
unii-4f05v145yr |
4f05v145yr , |
2-(3-(butyrylamino)-2,4,6-triiodobenzyl)butyric acid |
tyropanic acid |
benzenepropanoic acid, alpha-ethyl-2,4,6-triiodo-3-((1-oxobutyl)amino)- |
acidum tyropanoicum |
benzenepropanoic acid, a-ethyl-2,4,6-triiodo-3-[(1-oxobutyl)amino]- |
tyropanoate [vandf] |
tyropanoic acid [who-dd] |
benzenepropanoic acid, .alpha.-ethyl-2,4,6-triiodo-3-((1-oxobutyl)amino)- |
DTXSID5048269 |
SCHEMBL2788021 |
DB09340 |
Q6587055 |
2-(3-butyramido-2,4,6-triiodobenzyl)butanoic acid |
STARBLD0000838 |
EN300-18568448 |
2-[(3-butanamido-2,4,6-triiodophenyl)methyl]butanoic acid |
Class | Description |
---|---|
monocarboxylic acid | An oxoacid containing a single carboxy group. |
benzenes | Any benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 25 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 5 (15.63%) | 5.53% |
Reviews | 1 (3.13%) | 6.00% |
Case Studies | 1 (3.13%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 25 (78.13%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |